Mitogen-activated protein kinase kinase
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
| Mitogen-activated protein kinase kinase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC number | 2.7.12.2 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| |||||||||
MAP2K is classified as EC 2.7.12.2.
There are seven genes:
- MAP2K1 (a.k.a. MEK1)
- MAP2K2 (a.k.a. MEK2)
- MAP2K3 (a.k.a. MKK3)
- MAP2K4 (a.k.a. MKK4)
- MAP2K5 (a.k.a. MKK5)
- MAP2K6 (a.k.a. MKK6)
- MAP2K7 (a.k.a. MKK7)
The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]
Role in melanoma
MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.
gollark: *continues having absolutely no understanding of this conversation*
gollark: But it already has gone up to the "definitely really bad" bit in some regions.
gollark: https://xkcd.com/2278/
gollark: See, it's good to worry about and deal with things before they are an immediate and damaging problem.
gollark: 5% of the world is, as has been said, a lot of people, and exponential growth exists.
See also
References
- Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science. 267 (5198): 682–5. doi:10.1126/science.7839144. PMID 7839144.
- Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling. 16: 374–80. doi:10.1089/ars.2011.4034. PMC 3279717. PMID 21939387.
- Falchook, Gerald S.; Lewis, Karl D.; Infante, Jeffrey R.; Gordon, Michael S.; Vogelzang, Nicholas J.; DeMarini, Douglas J.; Fecher, Leslie A.; et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology. 13 (8): 782–789. doi:10.1016/S1470-2045(12)70269-3. PMC 4109286. PMID 22805292.
External links
- Mitogen-Activated+Protein+Kinase+Kinases at the US National Library of Medicine Medical Subject Headings (MeSH)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.